VRCA - Verrica Pharmaceuticals Inc.

6.32
-0.060   -0.949%

Share volume: 75,224
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$6.38
-0.06
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
30.31%
3 Months
-18.24%
6 Months
61.64%
1 Year
1,250.43%
2 Year
-6.92%
Key data
Stock price
$6.32
P/E Ratio 
N/A
DAY RANGE
$6.24 - $6.60
EPS 
-$0.87
52 WEEK RANGE
$0.39 - $9.82
52 WEEK CHANGE
$1,277.81
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
17.179 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
-0.21
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$99,452
AVERAGE 30 VOLUME 
$92,286
Company detail
CEO: Ted White
Region: US
Website: verrica.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Verrica Pharmaceuticals Inc. develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; VP-103 for treating plantar warts.

Recent news